Should You Buy Neumora Therapeutics, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Neumora Therapeutics, Inc. (NMRA) scores 4.7/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $0.47, our multi-model valuation analyzes whether the market has already discounted these weaknesses.
The short answer: 2 of 2 CirclFi valuation models project upside for Neumora Therapeutics, Inc. (NMRA) at $0.47 — the model consensus leans bullish, with a Quality Score of 4.7/10 and Value-Trap risk of 42/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Neumora Therapeutics, Inc. (NMRA) in 2026?
What Is the Bull Case vs the Bear Case for Neumora Therapeutics, Inc. (NMRA)?
| Bull case — $0.90 target (+90.3%) | Bear case |
|---|---|
| According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $0.47 and the median fair value of $0.70 implies +48.4% upside potential. | No active model flags significant downside for NMRA. The Value Trap score of 42/100 still argues for some caution. |
| According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model targets a fair value of $0.90 (+90.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | |
| Industry tailwind: breakthrough therapy designations could provide meaningful support for Neumora Therapeutics, Inc.'s revenue and margin trajectory in the Biotechnology space. |
How Does NMRA Compare to Its Biotechnology Peers?
Valuation data pages: ENGN · TYRA · ELAB · VIVS · ZNTL · LRMR · ESLA · ZEOX · MANE · EXEL · INCY
Which Other Stocks Score Like NMRA on Quality?
Closest companies to NMRA’s Quality of Company score of 4.7/10, across all industries.
- HLEO — Helio Corporation (QOC 4.7) · analysis
- BTX — BlackRock Innovation and Growth Term Trust (QOC 4.7) · analysis
- BNET — Bion Environmental Technologies, Inc. (QOC 4.7) · analysis
- TGL — Treasure Global Inc. (QOC 4.7) · analysis
- ARBB — ARB IOT Group Limited (QOC 4.7) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Biotechnology Screens Does NMRA Appear In?
So Is Neumora Therapeutics, Inc. (NMRA) Worth Buying in 2026?
The convergence of 4.7/10 quality, multi-model undervaluation (2/2 bullish, +48.4% median upside), and a median fair value of $0.70 vs. $0.47 current price makes Neumora Therapeutics, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Neumora Therapeutics, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About NMRA Stock?
Should I buy NMRA stock right now?
Based on CirclFi's multi-model analysis, 2 of 2 models see upside for NMRA at $0.47. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 4.7/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Neumora Therapeutics, Inc.?
Key risks include: an elevated Value Trap score of 42/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.7/10, indicating fundamental weakness; limited model coverage (2/13 active), reducing analytical confidence; general market and sector-specific risks affecting Biotechnology companies. Always diversify and consult a financial advisor.
How does NMRA compare to its competitors?
Among Biotechnology peers, NMRA holds a Quality Score of 4.7/10. Comparable companies include ENGN (QOC 4.7), TYRA (QOC 4.7), ELAB (QOC 4.7). The relative ranking helps investors identify whether NMRA offers better fundamental quality than alternatives in the same sector.
Is NMRA a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. NMRA's Quality Score of 4.7/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.
What price should I buy NMRA at?
CirclFi does not provide target buy prices or price alerts. However, our 2 active models produce fair value estimates ranging from $0.50 to $0.90. At $0.47, the stock trades below even the most conservative estimate, which may represent a margin of safety — or reflect risks the models don't capture. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for NMRA.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad